as declared in bloomberg
Allergan Buys Two Liver Disease Companies in Less Than a Day
Allergan Buys Two Liver Disease Companies in Less Than a Day
Allergan Plc is on a shopping spree.In less than 12 hours on Tuesday, the drugmaker announced a pair of acquisitions of companies developing treatments for a liver disease known as NASH, giving the company a ready-made pipeline in one of biotechnology's hottest areas.Before the market opened Tuesday, Allergan said it would buy Tobira Therapeutics Inc. for as much as $1.7 billion, gaining the company's experimental drugs for NASH, or non-alcoholic steatohepatitis.Then, after the market closed, it announced a $50 million deal to acquire Akarna Therapeutics Ltd., which is also developing NASH treatments.
in like manner go
Allergan Targets Liver Disease Drugs With Tobira Acquisition
Allergan Targets Liver Disease Drugs With Tobira AcquisitionBotox-maker Allergan is bulking up its drug pipeline with two acquisitions announced Tuesday, both of which target liver disease.Allergan PLC said it's acquiring Tobira Therapeutics Inc. and two potential liver disease treatments in a deal that could be worth almost $1.7 billion.Tobira is testing two treatments for non-alcoholic steatohepatitis, or NASH, a disease that triggers inflammation that can lead to cirrhosis, cancer and eventual liver failure.Allergan said it will pay $28.35 in cash up front for each Tobira share plus up to $49.84 in contingent value rights, depending on whether certain development, regulatory and commercial milestones are met.
besides nih
Fatty Liver Disease (Nonalcoholic Steatohepatitis)
Fatty Liver Disease (Nonalcoholic Steatohepatitis)
Nonalcoholic steatohepatitis or NASH is a common, often "silent" liver disease.It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol.The major feature in NASH is fat in the liver, along with inflammation and damage.Most people with NASH feel well and are not aware that they have a liver problem.
No comments:
Post a Comment